Ceftaroline Increases Membrane Binding and Enhances the Activity of Daptomycin against Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
New antimicrobial agents and novel combination therapies are needed to treat serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to daptomycin and vancomycin. The purpose of this study was to evaluate the combination of ceftaroline plus daptomycin or vancomycin in an in vitro pharmacokinetic/pharmacodynamic model. Simulations of ceftaroline-fosamil at 600 mg per kg of body weight every 8 h (q8h) (maximum free-drug concentration in serum [ fC max ], 15.2 mg/liter; half-life [ t 1/2 ], 2.3 h), daptomycin at 10 mg/kg/day ( f C max , 11.3 mg/liter; t 1/2 , 8 h), vancomycin at 2 g q12h ( fC max , 30 mg/liter; t 1/2 , 6 h), ceftaroline plus daptomycin, and ceftaroline plus vancomycin were evaluated against a clinical, isogenic MRSA strain pair: D592 (daptomycin susceptible and heterogeneous vancomycin intermediate) and D712 (daptomycin nonsusceptible and vancomycin intermediate) in a one-compartment in vitro pharmacokinetic/pharmacodynamic model over 96 h. Therapeutic enhancement of combinations was defined as ≥2 log 10 CFU/ml reduction over the most active single agent. The effect of ceftaroline on the membrane charge, cell wall thickness, susceptibility to killing by the human cathelicidin LL37, and daptomycin binding were evaluated. Therapeutic enhancement was observed with daptomycin plus ceftaroline in both strains and vancomycin plus ceftaroline against D592. Ceftaroline exposure enhanced daptomycin-induced depolarization (81.7% versus 72.3%; P = 0.03) and killing by cathelicidin LL37 ( P < 0.01) and reduced cell wall thickness ( P < 0.001). Fluorescence-labeled daptomycin was bound over 7-fold more in ceftaroline-exposed cells. Whole-genome sequencing and mutation analysis of these strains indicated that change in daptomycin susceptibility is related to an fmtC ( mprF ) mutation. The combination of daptomycin plus ceftaroline appears to be potent, with rapid and sustained bactericidal activity against both daptomycin-susceptible and -nonsusceptible strains of MRSA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C., Philippakis, A. A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,456
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Self-citationWhole genome sequencing of meticillin-resistant Staphylococcus aureus
Kuroda, M., Ohta, T., Uchiyama, I., Baba, T., Yuzawa, H., Kobayashi, I., Cui, L., Oguchi, A., Aoki, K.-I., Nagai, Y., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04403-2 · Cited by 1,961
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir034 · Cited by 1,599
Stampy: A statistical algorithm for sensitive and fast mapping of Illumina sequence reads
Lunter, G., & Goodson, M. (2011) · Genome Research · doi:10.1101/gr.111120.110 · Cited by 1,016
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Peschel, A., Jack, R. W., Otto, M., Collins, L. V., Staubitz, P., Nicholson, G., Kalbacher, H., Nieuwenhuizen, W. F., Jung, G., Tarkowski, A., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.9.1067 · Cited by 786
Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus
Silverman, J. A., Perlmutter, N. G., & Shapiro, H. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2538-2544.2003 · Cited by 656
Research works printed but not linked: 1
- 33. Sakoulas G, Rose WE. 2011. Effect of beta-lactam (BL) exposure in vitro on daptomycin (DAP) activity and cell wall thickness in MRSA, poster E-1332. Abstr. 51st Annu. Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL [Google Scholar]
Cited by
Items 101–134 of 134
Cheng, M. P., Lawandi, A., Butler‐Laporte, G., Paquette, K., & Lee, T. C. (2018) · Trials · doi:10.1186/s13063-018-2668-6 · Cited by 9
“However, using our modified tube coagulase test (Appendix), rapid MRSA testing (Appendix), and accounting for known MRSA colonization status [33] allows us to recruit patients into the study as close to presentation as possible, while maintaining specificity.”
BackgroundInfluentialWilsey, H. A., Burgess, D. R., & Burgess, D. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00360-20 · Cited by 9
Iyer, R. N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00212-7 · Cited by 21
Hall, A. M., & McTigue, S. M. (2018) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-23.6.490 · Cited by 8
Singh, K. V., Arias, C. A., & Murray, B. E. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02303-19 · Cited by 6
Kim, M., Ranganath, N., Chesdachai, S., Stevens, R. W., Sohail, M. R., & Saleh, O. A. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.08.011 · Cited by 5
Cusumano, J. A., Daffinee, K. E., Piehl, E. C., Garcia-Solache, M. A., Desbonnet, C. R., Rice, L. B., & LaPlante, K. L. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00426-22 · Cited by 6
Caniff, K. E., Judd, C., Lucas, K., Goro, S., Orzol, C., Eshaya, M., Musawa, M. A., Veve, M. P., & Rybak, M. J. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01068-0 · Cited by 4
Self-citationAdjunctive β-lactams for Staphylococcus aureus bacteremia: a narrative review
Chastain, D. B., White, B. P., Henao‐Martínez, A. F., Tu, P. J., Bland, C. M., Foster, R. A., & Cluck, D. B. (2025) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361251343969 · Cited by 6
“34,35 This process often reduces vancomycin minimum inhibitory concentrations (MICs), an effect known as the “see-saw effect,” which may contribute to improved therapeutic outcomes and potentially mitigate the emergence of resistance.”
Heger, M. L., & Al-Sayyad, B. (2022) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-27.8.754 · Cited by 8
Combination of ceftaroline and daptomycin as treatment for complicated osteomyelitis
Gascón, A., Castresana, M., Alzueta, N., Marin, M., Pío, M., & Echeverría, A. (2020) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2019-002183 · Cited by 4
Edmiston, C. E., Krepel, C. J., Leaper, D. J., Ledeboer, N. A., Mackey, T.-L. A., Graham, M. B., Lee, C. J., Rossi, P. J., Brown, K. R., Lewis, B. D., et al. (2014) · Surgical Infections · doi:10.1089/sur.2013.172 · Cited by 4
Updates on Combination Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia
Blackman, A. L., Rubin, E. C., Broadbent, E. K., & Brade, K. D. (2020) · Current Infectious Disease Reports · doi:10.1007/s11908-020-00737-8 · Cited by 5
Oh, S., Chau, R., Nguyễn, A. T., & Lenhard, J. R. (2021) · Antibiotics · doi:10.3390/antibiotics10060646 · Cited by 5
Donnelly, J., McDermott, H., Gash, S., O'Connor, C., O’Connell, K., O’Donnell, S., Dinesh, B., Burns, K., & Fitzpatrick, F. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.02.018 · Cited by 3
Werth, B. J., Zhang, R., Beltran, I. A. B., Penewit, K. M., Waalkes, A., Holmes, E. A., Salipante, S. J., & Xu, L. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf042 · Cited by 3
Self-citationReinert, J. P., Brown, M., & Ofori, R. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211021421 · Cited by 3
Profiling the effect of nafcillin on HA-MRSA D592 using bacteriological and physiological mediaPreprint
Seif, Y., Poudel, S., Tsunemoto, H., Szubin, R., Meehan, M. J., Olson, C. A., Rajput, A., Alarcon, G., Lamsa, A., Dillon, N. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.30.070904 · Cited by 3
Self-citationBleick, C. R., Helden, S. R. V., Berti, A. D., Richa, R., Lehman, S. M., Bayer, A. S., & Rybak, M. J. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00699-25 · Cited by 3
Self-citationHeil, E. L., Shah, K. P., & Amoroso, A. (2014) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000000222 · Cited by 2
“It is hypothesized that ceftaroline's cell wall “damaging” effects could lead to a more rigid cell membrane and subsequent restoration of daptomycin susceptibility.(8) Current challenges with ceftaroline include the relative lack of data for the treatment of MRSA bacteremia and endocarditis, and appropriate dosing str…”
BackgroundMohammad, S., Aljumaa, S. A., Ghazal, H., Alnamous, A., Dhaheri, R. S. A., Almangour, T. A., & El‐Dahiyat, F. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2625377 · Cited by 2
“In vitro studies have demonstrated synergistic effects when combined with vancomycin or daptomycin, including enhanced membrane depolarization, increased daptomycin binding, and accelerated bacterial killing, particularly in iso-lates with elevated vancomycin or daptomycin MICs [27,28].”
Meena, D. S., Kumar, D., & Bohra, G. K. (2026) · Infection · doi:10.1007/s15010-026-02815-w · Cited by 3
“This allows enhanced daptomycin binding and effective killing [48, 49].”
Cave, K., & Gould, I. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00138-9 · Cited by 2
Therapeutic Options for Resistant Gram Positives
Menon, V., & van Hal, S. J. (2014) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-014-0028-y
Nouvelles associations dans le traitement des infections graves à cocci à Gram positif
Fernandez‐Gerlinger, M., & Mainardi, J. (2014) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2014.01.003 · Cited by 1
Left-Sided MRSA Endocarditis Successfully Treated with a Combination of Daptomycin and Ceftaroline
Tejada, C. D. J., & Wenzel, R. P. (2015) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2015.03.002
Observation of ''Seesaw Effect'' with Vancomycin, Teicoplanin, Daptomycin and Ceftaroline in 150
Ireland, E., & Rybak, J. M. (2014)
Tennant, S. (2016) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2016.298
“However, S. aureus has developed decreased susceptibility to the drug through alterations in cell wall thickness 20 and overproduction of antimicrobial targets.48,50 Individual S. aureus microbes with decreased susceptibility can exist as subpopulations of an otherwise susceptible isolates, a phenomenon known as hVISA.”
BackgroundInfluentialAntimicrobial Resistance in Staphylococci aureus: Mechanisms of Resistance and Clinical Significance
Levine, D. P., & John, J. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-47266-9_4
Smith, J. R., Claeys, K. C., Zasowski, E. J., Yim, J., & Rybak, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-46718-4_21
Self-citationCombined Antimicrobial Therapy for Infective Endocarditis
Gomez-Villegas, S. I., Miller, W. R., & Arias, C. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-65839-6_16
Ceftaroline for Methicillin-Resistant Staphylococcus aureus Endovascular Infection
Cosimi, R. A., Peña, K., Lock, J. L., Riccobene, T. A., Nana, B., & Sakoulas, G. (2026) · Infectious Diseases and Therapy · doi:10.1007/s40121-026-01353-0
“A key topic of interest regarding ceftaroline for serious infections is the potential benefits of combination therapy, based on ceftaroline’s status as a β -lactam antibiotic and notable results from in vitro studies [25–27].”
Self-citationSanderford, V., Tabliago, N. R. A., Alnami, S., Spencer, S., Colven, R. B., Alvira-Arill, G. R., Gruss, Z. P., Ehrenberger, L., Hamby, A., Kosharek, A., et al. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.00442-26
“Different from most other β-lactam agents, the fifth-generation cephalosporin ceftaroline has activity against MRSA through its affinity for the mecA-encoded penicillin-binding protein 2a and has demonstrated in vitro synergy when combined with vancomycin and daptomycin (9, 10).”
Woischnig, A.-K., Küehl, R., Cornillet, D., Iizuka, A., Schumacher, M., Lang, C., Egli, A., Keller, P. M., Giulieri, S. G., Morgenstern, M., et al. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00876-26
“This therapeutic advantage is particularly relevant, given the increasing challenge posed by MRSE, which exhibits resistance not only to RIF, as emphasized in this study, but also to other key antibiotic classes such as fluoroquinolones, tetracyclines, and lipopeptides such as DAP (43).”
Metadata
- Authors
- Werth, B. J., Sakoulas, G., Rose, W. E., Pogliano, J., Tewhey, R., & Rybak, M. J.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- New York Medical College (US)
- University of Wisconsin–Madison (US)
- University of California San Diego (US)
- Scripps Research Institute (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2013-01
- Volume
- 57
- Issue
- 1
- Pages
- 66-73
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3535972
- OpenAlex
- W2138194474
- Semantic Scholar
- 39f34553cf23e3b9cdab27a62a417c2840f7a855
- Cited by
- 134
- References
- 40
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 11 · 2020: 13 · 2019: 8 · 2018: 8 · 2017: 7 · 2016: 11 · 2015: 12 · 2014: 19 · 2013: 12
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Update notices
- correction (2013-02-14)
- Open access
- green
- europepmc.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (R21A1092055-01)
- National Center for Research Resources (UL1RR025774)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- ceftaroline, daptomycin, vancomycin-intermediate Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, combination antibiotic therapy, pharmacokinetic-pharmacodynamic modeling, membrane depolarization, cell wall thickness, ceftaroline fosamil
- MeSH terms
- Ceftaroline, Anti-Bacterial Agents, Bacterial Proteins, Cell Membrane, Cell Wall, Cephalosporins, Drug Combinations, Drug Synergism, Fluorescent Dyes, Models, Biological, Mutation, Vancomycin, Colony Count, Microbial, Genome, Bacterial, Daptomycin, Aminoacyltransferases, Vancomycin Resistance, Antimicrobial Cationic Peptides, Microbial Viability, Cathelicidins, Methicillin-Resistant Staphylococcus aureus, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.